Home » Healthcare » Pharmaceuticals » Prostate Cancer Treatment Market

Prostate Cancer Treatment Market

Prostate Cancer Treatment Market By Treatment Type (Chemotherapy, Biological Therapy, Hormone Therapy) By Distribution (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies) By Region – Growth, Future Prospects And Competitive Analysis 2020 – 2030

Summary
Table Of Content

Market Overview

Report Coverage	Details
Market Size in 2022	USD 12,415.6 Million
Market Size by 2030	USD 21,425.39 Million
Growth Rate from 2023 to 2030	CAGR of 8.11%
Largest Market	North America
Base Year	2022
Forecast Period	2023 to 2030
Segments Covered	By Treatment Type, Hormone Therapy, and By Distribution
Regions Covered	North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

The market for prostate cancer treatment is witnessing substantial growth, with projected revenues to rise from USD 12,415.6 million in 2022 to an estimated USD 21,425.39 million by 2030. This projection signifies a compound annual growth rate (CAGR) of 8.11% from 2023 to 2030. With an increasing global demand for effective treatment methods, the opportunities within this market are expanding.

The market encompasses various diagnostic measures and therapeutic methods, including PSA tests, biopsies, MRI scans, and treatments such as radiation therapy, chemotherapy, hormone therapy, and immunotherapy. Driving factors behind this market growth include the surge in prostate cancer cases, advancements in medical technology, and the rise in global healthcare spending. According to the American Cancer Society (ACS), there are over 12 million new cancer diagnoses worldwide each year, with prostate cancer cases accounting for 99% of those predominantly seen after the age of 50.

Innovations in screening and diagnostic technologies are propelling the adoption of therapeutics. Breakthrough therapies utilize bioinformatics and computational biology to optimize treatment, with techniques like proteome profiling, exome sequencing, and whole-genome sequencing revolutionizing the development of cures and treatments. For instance, in 2022, a phase III trial for Olaparib involved over 4,000 men, utilizing tumor genomic testing for patient identification.

The escalating prevalence of prostate cancer has resulted in increased investments in research and development, with pharmaceutical giants and biotechnology companies collaborating to enhance treatment options. Government and nonprofit initiatives aimed at raising awareness are expected to improve early detection rates and enhance treatment effectiveness. Additionally, telemedicine solutions for remote patient monitoring, virtual consultations, and personalized care have gained traction due to the ongoing COVID-19 pandemic, leading to improved outcomes for prostate cancer patients.

Governments and healthcare organizations are also implementing policies to reduce treatment costs, making them more accessible to patients from diverse socioeconomic backgrounds. Moreover, there is a growing trend towards personalized medicine, where treatments are tailored to individual patient profiles based on genetic predispositions and disease progression patterns.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research!

Download Sample

Market Growth Drivers and Trends

The progressive expansion of the prostate cancer treatment market is propelled by several key trends and growth factors. One notable trend is the increasing strategic collaborations and partnerships among major pharmaceutical and biotechnology companies. These collaborations aim to expedite the development and commercialization of innovative therapeutics for prostate cancer, leveraging shared expertise and resources to introduce effective therapies to the market and foster innovation.

Advancements in genetic testing and the growing significance of personalized medicine are driving the demand for more precise and targeted treatment options. The emergence of therapies tailored to the unique genetic profile of the patient’s tumor fuels the need for next-generation treatments on the market.

The rising awareness about prostate cancer and the importance of early detection play a vital role in driving growth. This has resulted in increased routine screenings and subsequent diagnoses, creating a higher demand for effective therapies.

The prevalence of prostate cancer, especially among aging populations, significantly contributes to the ongoing demand for improved treatments. As this demographic trend continues, it is expected to consistently drive growth in the prostate cancer treatment market in the future.

Market restraint factors

Despite the promising growth prospects, the market for prostate cancer treatment is confronted with various challenges. One significant barrier is the substantial cost associated with these treatments, particularly for advanced therapies and diagnostic procedures. Limited healthcare budgets and inadequate insurance coverage in many regions further exacerbate this issue, rendering these treatments inaccessible to a significant portion of the population.

Another constraint is the stringent regulatory guidelines and protracted approval process for new drugs, which can impede the entry of innovative treatments into the market. This sluggishness hampers the availability of potentially more effective therapies, thereby hindering market growth.

The side effects associated with prostate cancer treatments can discourage certain patients from pursuing these therapies. Chemotherapy, radiation therapy, and even some of the newer treatments can cause adverse effects, thus limiting the overall acceptance of these therapies on the market.

The lack of awareness and late-stage diagnosis in low-income and developing regions also restricts market growth. Inadequate access to regular health screenings in these regions reduces opportunities for early detection and treatment of prostate cancer. This challenge is compounded by limited healthcare infrastructure and a shortage of trained medical professionals in these areas.

By addressing these challenges, we can strive to improve access to affordable and effective prostate cancer treatments, ensuring better outcomes for patients worldwide.

Challenges and opportunities

The market for prostate cancer treatment, although brimming with growth prospects and a dynamic competitive landscape, is not without its challenges and opportunities. Key challenges include navigating stringent regulatory guidelines, high R&D costs, and maintaining a competitive edge in a market dominated by established pharmaceutical giants. These hurdles demand a strong focus on innovation, strategic partnerships, and understanding the evolving needs of patients and healthcare providers.

However, the market also presents significant opportunities. The increasing prevalence of prostate cancer, particularly in aging populations, creates a continuous demand for more effective and less toxic therapies. Emerging trends like personalized medicine offer the opportunity for innovation by providing treatments tailored to individual genetic profiles and disease characteristics. Furthermore, the development of novel therapies, such as PARP inhibitors for BRCA-mutated prostate cancer, opens up new avenues for market expansion. Additionally, developing regions with limited access to effective treatments represent untapped markets, where increasing awareness and building robust healthcare infrastructure could lead to substantial market growth. Therefore, while the challenges are significant, the opportunities for companies in the prostate cancer treatment market are vast and varied.

Regulatory Analysis

In the realm of prostate cancer treatment, regulatory authorities such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the National Medical Products Administration (NMPA) play a crucial role in overseeing the market. These bodies establish guidelines for the development, approval, and post-market surveillance of novel therapies, ensuring they meet high standards of quality, safety, and efficacy.

The FDA’s accelerated approval process is a significant regulatory pathway that allows quicker access to potentially life-saving treatments. However, obtaining approval through this pathway requires robust clinical data demonstrating substantial improvements over existing therapies. Meanwhile, the EMA utilizes a similar scheme known as the Conditional Marketing Authorization (CMA), offering early access to promising treatments under specific conditions.

Regulatory bodies also oversee post-market surveillance through systems such as adverse event reporting and risk evaluation and mitigation strategies (REMS), ensuring the continued safety and efficacy of approved drugs.

While the regulatory landscape does present potential obstacles, it also plays a fundamental role in maintaining the integrity of the prostate cancer treatment market, safeguarding patient interests, and fostering innovation. It is crucial for market players to stay informed about regulatory changes, align their strategies accordingly, and proactively engage with regulatory authorities to navigate the approval process efficiently.

Competitive Analysis

Prominent market players are committed to the development of innovative and advanced products. Several companies have a lineup of products scheduled for launch during the forecast period. For instance, in March 2022, Merck announced the initiation of the Keylynk-010 trial, evaluating the combination of Keytruda and Lynparza for patients with metastatic castration-resistant prostate cancer.

Leading Participants in the Market:

Johnson & Johnson Services, Inc.

Astellas Pharma, Inc.

Eli Lilly and Company

Sanofi

Ipsen Pharma

Bayer AG

AstraZeneca

Valeant Pharmaceuticals International, Inc.

Merck & Co., Inc.
Pfizer Inc.

Recent developments and news

In March 2022:

The US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer that has metastasized.
BioPharma launched camcevi (leuprolide), a 42-mg injection emulsion for the treatment of adults with advanced prostate cancer. Additionally, they introduced the AccordConnects mobile application for Camcevi inventory management.
The US FDA approved 177Lu-PSMA-617, a treatment for metastatic prostate cancer.
Merck initiated the keylynk-010 trial to assess keytruda combined with lynparza in patients with metastatic castration-resistant prostate cancer.

In January 2021:

The U.S. Food and Drug Administration (FDA) approved a new medication called Relugolix. Known as Orgovyx, this drug showed promising results in a significant clinical trial, successfully lowering testosterone levels in men with advanced prostate cancer, hinting at a potential shift in the treatment approach for the disease.

In June 2021:

Novartis AG announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation (BTD) to 177Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC). This designation is reserved for drugs showing early clinical promise in treating severe conditions, representing a potential substantial improvement over existing treatments.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Segmentation Analysis

Based on the treatment type, the prostate cancer treatment market is segmented into:

Biological therapy

Enzalutamide

Abiraterone

Leuprolide

Goserelin

Triptorelin

Histrelin

Degarelix

Sipuleucel-T

Chemotherapy

Mitotic inhibitors, e.g., Docetaxel, Cabazitaxel

Topoisomerase inhibitors, e.g., mitoxantrone

Alkylating antineoplastic agent, e.g., estramustine

According to market experts, biological therapy is considered the primary treatment option to reduce androgens in the body (testosterone and dihydrotestosterone), as they stimulate the growth of prostate cancer cells. However, the drug-related side effects are significant, leading patients to opt for chemotherapy. Chemotherapy involves prescribing drugs such as docetaxel, cabazitaxel, mitoxantrone, and estramustine for the treatment of prostate cancer. Chemotherapy is preferred for patients who have developed resistance to biological therapy and whose prostate cancer has spread outside the prostate gland, metastasizing in distant organs. In 2021, biological therapy held the largest market share in prostate cancer treatment, followed by chemotherapy. Targeted biological therapy is expected to witness significant growth between 2024 and 2027, driven by a promising pipeline. Factors such as improved reimbursement policies, an aging population with growing public awareness, and technological advancements in drug development contribute to the growth of this segment.

Hormone Therapy

In 2022, the hormonal therapy drug class dominated the market, accounting for 88.42% of the revenue share. Hormonal therapy encompasses drugs that function as luteinizing hormone-releasing hormone (LHRH) antagonists, luteinizing hormone-releasing hormone (LHRH) agonists, and anti-androgens. Among these drugs, Xtandi is widely used, with its usage increasing not only due to more prostate cancer patients receiving treatment but also because of longer treatment durations, averaging nine months. Xtandi generated revenue exceeding $3 billion in 2021. This trend is expected to continue as more urologists recommend hormonal therapy, contributing to the sustained revenue stream of Xtandi.

By Distribution

Hospital Pharmacies

Drug Stores and Retail Pharmacies

Online Pharmacies

Or, for the purpose of this study, the global prostate cancer treatment market is categorized into:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

In 2021, North America was identified as the largest market for prostate cancer treatment. According to the American Cancer Society, there will be approximately 161,360 new cases of prostate cancer in 2017, primarily due to an aging population and high public awareness, leading to early diagnosis and treatment. Cancer Research UK reports that prostate cancer accounts for 26% of all new cancer cases in males. Europe is expected to be the second-largest market, driven by rising public awareness, improved healthcare infrastructure, awareness activities, and supportive reimbursement policies by government and non-government organizations. Newly approved drug molecules for the treatment of pancreatic cancer have gained acceptance and penetration in the European market. The growth of the Asia Pacific prostate cancer treatment market is attributed to factors such as the increasing prevalence of the disease, investments in R&D, and higher disposable income in these regions. The rapid growth of the prostate cancer treatment market in Latin America, the Middle East, and Africa is fueled by developing health infrastructure, increasing awareness about healthcare, and an aging population.

Chapter No. 1 :………. Introduction 21

1.1. Report Description. 21

1.1.1. Purpose of the Report 21

1.1.2. USP & Key Offerings. 21

1.2. Key Benefits for Stakeholders. 21

1.3. Target Audience. 22

1.4. Report Scope 23

Chapter No. 2 :………. Executive Summary. 25

2.1. Prostate Cancer Therapeutics Market Snapshot. 25

2.2. Global Prostate Cancer Therapeutics Market, 2017 – 2022 (USD Million) 26

Chapter No. 3 :………. Impact Analysis of COVID 19 & Russia-Ukraine War on Prostate Cancer Therapeutics Market. 27

3.1. Impact Assessment of COVID-19 Pandemic, By Region. 27

3.1.1. Supply chain disruptions. 27

3.1.2. Demand fluctuations. 27

3.1.3. Shift in product mix. 27

3.1.4. Reduced industrial activity. 27

3.1.5. Temporary disruptions and delays. 27

3.1.6. Shift in focus towards essential services. 27

3.2. Russia-Ukraine War Impacts. 28

3.2.1. Uncertainty and economic instability. 28

3.2.2. Supply chain disruptions. 28

3.2.3. Regional market shifts. 28

3.2.4. Shift in government priorities. 28

Chapter No. 4 :………. Prostate Cancer Therapeutics Market – Industry Analysis. 29

4.1. Introduction 29

4.2. Market Drivers 30

4.2.1. Driving Factor 1 Analysis. 30

4.2.2. Driving Factor 2 Analysis. 31

4.3. Market Restraints. 32

4.3.1. Restraining Factor Analysis. 32

4.4. Market Opportunities. 33

4.4.1. Market Opportunity Analysis. 33

4.5. Porter’s Five Forces Analysis. 34

4.6. Value Chain Analysis. 35

4.7. Buying Criteria 36

Chapter No. 5 :………. Analysis Competitive Landscape. 37

5.1. Company Market Share Analysis – 2022. 37

5.1.1. Global Prostate Cancer Therapeutics Market: Company Market Share, by Revenue2022. 37

5.1.2. Global Prostate Cancer Therapeutics Market: Top 6 Company Market Share, by Revenue2022. 37

5.1.3. Global Prostate Cancer Therapeutics Market: Top 3 Company Market Share, by Revenue2022. 38

5.1. Global Prostate Cancer Therapeutics Market Company Revenue Market Share, 2022. 39

5.2. Company Assessment Metrics, 2022. 40

5.2.1. Stars 40

5.2.2. Emerging Leaders. 40

5.2.3. Pervasive Players. 40

5.2.4. Participants. 40

5.3. Start-ups /SMEs Assessment Metrics, 2022. 40

5.3.1. Progressive Companies. 40

5.3.2. Responsive Companies. 40

5.3.3. Dynamic Companies. 40

5.3.4. Starting Blocks. 40

5.4. Strategic Developments. 41

5.4.1. Acquisitions & Mergers. 41

5.4.2. New Product Launch. 41

5.4.3. Regional Expansion. 41

5.5. Key Players Product Matrix. 42

Chapter No. 6 :………. PESTEL & Adjacent Market Analysis. 43

6.1. PESTEL 43

6.1.1. Political Factors. 43

6.1.2. Economic Factors. 43

6.1.3. Social Factors. 43

6.1.4. Technological Factors. 43

6.1.5. Environmental Factors. 43

6.1.6. Legal Factors. 43

6.2. Adjacent Market Analysis. 43

Chapter No. 7 :………. Prostate Cancer Therapeutics Market – By Type Segment Analysis. 44

7.1. Prostate Cancer Therapeutics Market Overview, by Type Segment. 44

7.1.1. Prostate Cancer Therapeutics Market Revenue Share, By Type, 2022 & 2030. 45

7.1.2. Prostate Cancer Therapeutics Market Attractiveness Analysis, By Type. 46

7.1.3. Incremental Revenue Growth Opportunity, by Type, 2023 – 2030. 46

7.1.4. Prostate Cancer Therapeutics Market Revenue, By Type, 2017, 2022, 2026 & 2030. 47

7.2. Chemotherapy 48

7.2.1. Global Chemotherapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 49

7.2.2. Global Chemotherapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 49

7.3. Biological Therapy. 50

7.3.1. Global Biological Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 51

7.3.2. Global Biological Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 51

7.4. Hormone Therapy. 52

7.4.1. Global Hormone Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 53

7.4.2. Global Hormone Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 53

Chapter No. 8 :………. Prostate Cancer Therapeutics Market – By Distribution Channel Segment Analysis. 54

8.1. Prostate Cancer Therapeutics Market Overview, by Distribution Channel Segment. 54

8.1.1. Prostate Cancer Therapeutics Market Revenue Share, By Distribution Channel , 2022 & 2030. 55

8.1.2. Prostate Cancer Therapeutics Market Attractiveness Analysis, By Distribution Channel 56

8.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel , 2023 – 2030. 56

8.1.4. Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017, 2022, 2026 & 2030. 57

8.2. Hospital Pharmacies. 58

8.2.1. Global Hospital Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 59

8.2.2. Global Hospital Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 59

8.3. Drug Stores & Retail Pharmacies. 60

8.3.1. Global Drug Stores & Retail Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 61

8.3.2. Global Drug Stores & Retail Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 61

8.4. Online Pharmacies. 62

8.4.1. Global Online Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 63

8.4.2. Global Online Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 63

Chapter No. 9 :………. Prostate Cancer Therapeutics Market – Regional Analysis. 64

9.1. Prostate Cancer Therapeutics Market Overview, by Regional Segments 64

9.2. Region 65

9.2.1. Global Prostate Cancer Therapeutics Market Revenue Share, By Region, 2022 & 2030. 65

9.2.2. Prostate Cancer Therapeutics Market Attractiveness Analysis, By Region. 66

9.2.3. Incremental Revenue Growth Opportunity, by Region, 2023 – 2030. 66

9.2.4. Prostate Cancer Therapeutics Market Revenue, By Region, 2017, 2022, 2026 & 2030. 67

9.2.5. Global Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 68

9.2.6. Global Prostate Cancer Therapeutics Market Revenue, By Region, 2023 – 2030 (USD Million) 68

9.3. Type 69

9.3.1. Global Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 69

9.3.2. Global Prostate Cancer Therapeutics Market Revenue, By Type, 2023 – 2030 (USD Million) 69

9.4. Distribution Channel 70

9.4.1. Global Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 70

9.4.2. Global Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023 – 2030 (USD Million) 70

Chapter No. 10 :…….. Prostate Cancer Therapeutics Market – North America.. 71

10.1. North America 71

10.1. Key Highlights 71

10.1.1. North America Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 72

10.1.2. North America Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 73

10.1.3. North America Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 74

10.1.4. U.S. 75

10.1.5. Canada 75

10.1.6. Mexico 75

Chapter No. 11 :…….. Prostate Cancer Therapeutics Market – Europe. 76

11.1. Europe 76

11.2. Key Highlights 76

11.2.1. Europe Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 77

11.2.2. Europe Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 79

11.2.3. Europe Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 80

11.2.4. UK 81

11.2.5. France 81

11.2.6. Germany. 81

11.2.7. Italy 81

11.2.8. Spain 81

11.2.9. Russia 81

11.2.10. BENELUX. 81

11.2.11. Sweden. 81

11.2.12. Denmark. 81

11.2.13. Poland. 81

11.2.14. Austria. 81

11.2.15. Rest of Europe. 81

Chapter No. 12 :…….. Prostate Cancer Therapeutics Market – Asia Pacific. 82

12.1. Asia Pacific 82

12.2. Key Highlights 82

12.2.1. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 83

12.2.2. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 85

12.2.3. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 86

12.2.4. China 87

12.2.5. Japan 87

12.2.6. South Korea. 87

12.2.7. India 87

12.2.8. Thailand. 87

12.2.9. Indonesia. 87

12.2.10. Vietnam.. 87

12.2.11. Malaysia. 87

12.2.12. Philippines. 87

12.2.13. Taiwan. 87

12.2.14. Rest of Asia Pacific. 87

Chapter No. 13 :…….. Prostate Cancer Therapeutics Market – Latin America.. 88

13.1. Latin America 88

13.2. Key Highlights 88

13.2.1. Latin America Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 89

13.2.2. Latin America Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 90

13.2.3. Latin America Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 91

13.2.4. Brazil 92

13.2.5. Argentina. 92

13.2.6. Colombia. 92

13.2.7. Chile 92

13.2.8. Peru 92

13.2.9. Rest of Latin America. 92

Chapter No. 14 :…….. Prostate Cancer Therapeutics Market – Middle East. 93

14.1. The Middle-East. 93

14.2. Key Highlights 93

14.2.1. Middle East Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 94

14.2.2. Middle East Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 95

14.2.3. Middle East Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 96

14.2.4. GCC Countries. 97

14.2.5. Israel 97

14.2.6. Turkey 97

14.2.7. Iran 97

14.2.8. Rest of Middle East & Africa. 97

Chapter No. 15 :…….. Prostate Cancer Therapeutics Market – Africa.. 98

15.1. Africa 98

15.2. Key Highlights 98

15.2.1. Africa Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 99

15.2.2. Africa Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 100

15.2.3. Africa Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 101

15.2.4. South Africa. 102

15.2.5. Egypt 102

15.2.6. Nigeria 102

15.2.7. Algeria 102

15.2.8. Morocco. 102

15.2.9. Rest of Africa. 102

Chapter No. 16 :…….. Company Profiles. 103

16.1. Johnson & Johnson Services, Inc. 103

16.1.1. Company Overview.. 103

16.1.2. Product Portfolio. 103

16.1.3. Swot Analysis. 103

16.1.4. Business Strategy. 104

16.1.5. Financial Overview.. 104

16.2. Astellas Pharma Inc. 105

16.3. Eli Lilly and Company. 105

16.4. Sanofi 105

16.5. Ipsen Pharma 105

16.6. Bayer AG 105

16.7. AstraZeneca 105

16.8. Valeant Pharmaceuticals International, Inc. 105

16.9. Merck & Co., Inc. 105

16.10. Pfizer Inc. 105

Chapter No. 17 :…….. Research Methodology. 106

17.1. Research Methodology. 106

17.2. Phase I – Secondary Research. 107

17.3. Phase II – Data Modeling. 107

17.3.1. Company Share Analysis Model 108

17.3.2. Revenue Based Modeling. 108

17.4. Phase III – Primary Research. 109

17.5. Research Limitations. 110

17.5.1. Assumptions. 110

List of Figures

FIG NO. 1……….. Global Prostate Cancer Therapeutics Market Revenue, 2017 – 2022 (USD Million) 26

FIG NO. 2……….. Porter’s Five Forces Analysis for Global Prostate Cancer Therapeutics Market 34

FIG NO. 3……….. Value Chain Analysis for Global Prostate Cancer Therapeutics Market 35

FIG NO. 4……….. Company Share Analysis, 2022. 37

FIG NO. 5……….. Company Share Analysis, 2022. 37

FIG NO. 6……….. Company Share Analysis, 2022. 38

FIG NO. 7……….. Prostate Cancer Therapeutics Market – Company Revenue Market Share, 2022. 39

FIG NO. 8……….. Prostate Cancer Therapeutics Market Revenue Share, By Type, 2022 & 2030. 45

FIG NO. 9……….. Market Attractiveness Analysis, By Type. 46

FIG NO. 10……… Incremental Revenue Growth Opportunity by Type. 46

FIG NO. 11……… Prostate Cancer Therapeutics Market Revenue, By Type, 2017, 2022, 2026 & 2030. 47

FIG NO. 12……… Global Prostate Cancer Therapeutics Market for Chemotherapy, Revenue (USD Million) 2017 – 2030. 48

FIG NO. 13……… Global Prostate Cancer Therapeutics Market for Biological Therapy, Revenue (USD Million) 2017 – 2030. 50

FIG NO. 14……… Global Prostate Cancer Therapeutics Market for Hormone Therapy, Revenue (USD Million) 2017 – 2030. 52

FIG NO. 15……… Prostate Cancer Therapeutics Market Revenue Share, By Distribution Channel , 2022 & 2030. 55

FIG NO. 16……… Market Attractiveness Analysis, By Distribution Channel 56

FIG NO. 17……… Incremental Revenue Growth Opportunity by Distribution Channel 56

FIG NO. 18……… Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017, 2022, 2026 & 2030. 57

FIG NO. 19……… Global Prostate Cancer Therapeutics Market for Hospital Pharmacies, Revenue (USD Million) 2017 – 2030. 58

FIG NO. 20……… Global Prostate Cancer Therapeutics Market for Drug Stores & Retail Pharmacies, Revenue (USD Million) 2017 – 2030. 60

FIG NO. 21……… Global Prostate Cancer Therapeutics Market for Online Pharmacies, Revenue (USD Million) 2017 – 2030. 62

FIG NO. 22……… Global Prostate Cancer Therapeutics Market Revenue Share, By Region, 2022 & 2030. 65

FIG NO. 23……… Market Attractiveness Analysis, By Region. 66

FIG NO. 24……… Incremental Revenue Growth Opportunity by Region. 66

FIG NO. 25……… Prostate Cancer Therapeutics Market Revenue, By Region, 2017, 2022, 2026 & 2030. 67

FIG NO. 26……… North America Prostate Cancer Therapeutics Market Revenue, 2017 – 2022 (USD Million) 71

FIG NO. 27……… Europe Prostate Cancer Therapeutics Market Revenue, 2017 – 2022 (USD Million) 76

FIG NO. 28……… Asia Pacific Prostate Cancer Therapeutics Market Revenue, 2017 – 2022 (USD Million) 82

FIG NO. 29……… Latin America Prostate Cancer Therapeutics Market Revenue, 2017 – 2022 (USD Million) 88

FIG NO. 30……… The Middle-East Prostate Cancer Therapeutics Market Revenue, 2017 – 2022 (USD Million) 93

FIG NO. 31……… Africa Prostate Cancer Therapeutics Market Revenue, 2017 – 2022 (USD Million) 98

FIG NO. 32……… Research Methodology – Detailed View.. 106

FIG NO. 33……… Research Methodology. 107

List of Tables

TABLE NO. 1. :…. Global Prostate Cancer Therapeutics Market: Snapshot 25

TABLE NO. 2. :…. Drivers for the Prostate Cancer Therapeutics Market: Impact Analysis. 30

TABLE NO. 3. :…. Restraints for the Prostate Cancer Therapeutics Market: Impact Analysis. 32

TABLE NO. 4. :…. Global Chemotherapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 49

TABLE NO. 5. :…. Global Chemotherapy Prostate Cancer Therapeutics Market Revenue, By Region, 2023– 2030 (USD Million) 49

TABLE NO. 6. :…. Global Biological Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 51

TABLE NO. 7. :…. Global Biological Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2023– 2030 (USD Million) 51

TABLE NO. 8. :…. Global Hormone Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 53

TABLE NO. 9. :…. Global Hormone Therapy Prostate Cancer Therapeutics Market Revenue, By Region, 2023– 2030 (USD Million) 53

TABLE NO. 10. :.. Global Hospital Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 59

TABLE NO. 11. :.. Global Hospital Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2023– 2030 (USD Million) 59

TABLE NO. 12. :.. Global Drug Stores & Retail Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 61

TABLE NO. 13. :.. Global Drug Stores & Retail Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2023– 2030 (USD Million) 61

TABLE NO. 14. :.. Global Online Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 63

TABLE NO. 15. :.. Global Online Pharmacies Prostate Cancer Therapeutics Market Revenue, By Region, 2023– 2030 (USD Million) 63

TABLE NO. 16. :.. Global Prostate Cancer Therapeutics Market Revenue, By Region, 2017 – 2022 (USD Million) 68

TABLE NO. 17. :.. Global Prostate Cancer Therapeutics Market Revenue, By Region, 2023– 2030 (USD Million) 68

TABLE NO. 18. :.. Global Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 69

TABLE NO. 19. :.. Global Prostate Cancer Therapeutics Market Revenue, By Type, 2023– 2030 (USD Million) 69

TABLE NO. 20. :.. Global Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 70

TABLE NO. 21. :.. Global Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023– 2030 (USD Million) 70

TABLE NO. 22. :.. North America Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 72

TABLE NO. 23. :.. North America Prostate Cancer Therapeutics Market Revenue, By Country, 2023– 2030 (USD Million) 72

TABLE NO. 24. :.. North America Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 73

TABLE NO. 25. :.. North America Prostate Cancer Therapeutics Market Revenue, By Type, 2023– 2030 (USD Million) 73

TABLE NO. 26. :.. North America Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 74

TABLE NO. 27. :.. North America Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023– 2030 (USD Million) 74

TABLE NO. 28. :.. Europe Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 77

TABLE NO. 29. :.. Europe Prostate Cancer Therapeutics Market Revenue, By Country, 2023– 2030 (USD Million) 77

TABLE NO. 30. :.. Europe Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 79

TABLE NO. 31. :.. Europe Prostate Cancer Therapeutics Market Revenue, By Type, 2023– 2030 (USD Million) 79

TABLE NO. 32. :.. Europe Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 80

TABLE NO. 33. :.. Europe Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023– 2030 (USD Million) 80

TABLE NO. 34. :.. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 83

TABLE NO. 35. :.. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Country, 2023– 2030 (USD Million) 83

TABLE NO. 36. :.. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 85

TABLE NO. 37. :.. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Type, 2023– 2030 (USD Million) 85

TABLE NO. 38. :.. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 86

TABLE NO. 39. :.. Asia Pacific Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023– 2030 (USD Million) 86

TABLE NO. 40. :.. Latin America Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 89

TABLE NO. 41. :.. Latin America Prostate Cancer Therapeutics Market Revenue, By Country, 2023– 2030 (USD Million) 89

TABLE NO. 42. :.. Latin America Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 90

TABLE NO. 43. :.. Latin America Prostate Cancer Therapeutics Market Revenue, By Type, 2023– 2030 (USD Million) 90

TABLE NO. 44. :.. Latin America Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 91

TABLE NO. 45. :.. Latin America Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023– 2030 (USD Million) 91

TABLE NO. 46. :.. Middle East Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 94

TABLE NO. 47. :.. Middle East Prostate Cancer Therapeutics Market Revenue, By Country, 2023– 2030 (USD Million) 94

TABLE NO. 48. :.. Middle East Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 95

TABLE NO. 49. :.. Middle East Prostate Cancer Therapeutics Market Revenue, By Type, 2023– 2030 (USD Million) 95

TABLE NO. 50. :.. Middle East Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 96

TABLE NO. 51. :.. Middle East Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023– 2030 (USD Million) 96

TABLE NO. 52. :.. Africa Prostate Cancer Therapeutics Market Revenue, By Country, 2017 – 2022 (USD Million) 99

TABLE NO. 53. :.. Africa Prostate Cancer Therapeutics Market Revenue, By Country, 2023– 2030 (USD Million) 99

TABLE NO. 54. :.. Africa Prostate Cancer Therapeutics Market Revenue, By Type, 2017 – 2022 (USD Million) 100

TABLE NO. 55. :.. Africa Prostate Cancer Therapeutics Market Revenue, By Type, 2023– 2030 (USD Million) 100

TABLE NO. 56. :.. Africa Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2017 – 2022 (USD Million) 101

TABLE NO. 57. :.. Africa Prostate Cancer Therapeutics Market Revenue, By Distribution Channel , 2023– 2030 (USD Million) 101

Frequently Asked Questions

What is the projected growth of the prostate cancer treatment market?

The prostate cancer treatment market is expected to grow from USD 12,415.6 million in 2022 to an estimated USD 21,425.39 million by 2030, with a compound annual growth rate (CAGR) of 8.11% from 2023 to 2030.

What are the key drivers and trends in the prostate cancer treatment market?

Major drivers include the increase in prostate cancer cases, advancements in medical technology, rise in global healthcare spending, and innovations in screening and diagnostic technologies. A significant trend is the rise in strategic collaborations and partnerships among major pharmaceutical and biotech companies, the growing significance of personalized medicine, and increased routine screenings.

What challenges does the prostate cancer treatment market face?

The market faces challenges like high treatment costs, stringent regulatory guidelines, adverse side effects associated with treatments, and lack of awareness and late-stage diagnosis in developing regions.

Who are the leading participants in the prostate cancer treatment market?

Leading market players include Johnson & Johnson Services, Inc., Astellas Pharma, Inc., Eli Lilly and Company, Sanofi, Ipsen Pharma, Bayer AG, AstraZeneca, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Pfizer Inc.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$7699

Let us help you

MIKE, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

EMAIL US

Request Sample

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –